D
Celldex Therapeutics, Inc. CLDX
$23.50 -$0.35-1.47% NASDAQ
Recommendation
Prev Close
$26.73
Volume
70,510
Avg Vol (90D)
1,151,163
Market Cap
$1.78B
Dividend & Yield
--
52-Week Range
$14.40 - $29.05
P/E (TTM)
--
EPS (TTM)
-$3.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Celldex Therapeutics (CLDX, $24.75) price may climb as it broke lower Bollinger Band on Nov 03, 2025
11/4/2025 - Tickeron - Stocks
Y Intercept Hong Kong Ltd Takes $1.19 Million Position in Celldex Therapeutics, Inc. $CLDX
11/4/2025 - MarketBeat
Celldex Therapeutics (CLDX): Assessing Valuation After Promising CDX-622 Phase 1 Results Presented
11/3/2025 - Simply Wall St
Positive Early CDX-622 Data Might Change The Case For Investing In Celldex Therapeutics (CLDX)
11/1/2025 - Simply Wall St
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
10/30/2025 - Globe Newswire
Celldex Therapeutics (CLDX) to Release Quarterly Earnings on Wednesday
10/30/2025 - MarketBeat
Surprising Analyst 12-Month Target For FYC
10/30/2025 - ETF Channel
Weiss Ratings Reaffirms Sell (D-) Rating for Celldex Therapeutics (NASDAQ:CLDX)
10/26/2025 - MarketBeat
Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Cautious Coverage and Renewed Safety Concerns
10/24/2025 - Simply Wall St
Celldex Therapeutics (CLDX, $26.26) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 23, 2025
10/24/2025 - Tickeron - Stocks
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Analysts
10/24/2025 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Upgraded to Strong-Buy at Mizuho
10/23/2025 - MarketBeat
Mizuho Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX)
10/23/2025 - Ticker Report
Celldex Therapeutics (CLDX, $27.91) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 22, 2025
10/23/2025 - Tickeron - Technical Analysis
Could Safety Concerns Raised by Barclays Shift Perceptions of Celldex Therapeutics' (CLDX) Competitive Edge?
10/22/2025 - Simply Wall St
Celldex Therapeutics (CLDX, $27.91) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 21, 2025
10/22/2025 - Tickeron - Technical Analysis
TD Asset Management Inc Increases Holdings in Celldex Therapeutics, Inc. $CLDX
10/22/2025 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Earns Outperform Rating from Analysts at Mizuho
10/21/2025 - MarketBeat
Celldex Therapeutics (CLDX, $27.67) Stochastic Oscillator left the overbought zone on October 20, 2025
10/21/2025 - Tickeron - Technical Analysis
Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating
10/21/2025 - Insider Monkey
11 Best Small Cap Stocks with the Highest Upside
10/20/2025 - Insider Monkey
Celldex Therapeutics (CLDX, $26.55) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 16, 2025
10/17/2025 - Tickeron - Stocks
Celldex Therapeutics (CLDX): Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor Focus
10/15/2025 - Simply Wall St
Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?
10/15/2025 - MarketBeat
How Investors Are Reacting To Celldex Therapeutics (CLDX) After Barclays Shines Spotlight on Biotech Innovation
10/13/2025 - Simply Wall St
Income Statement
Total Revenue (TTM)
$5.79M
EBITDA (TTM)
-$231.40M
EBIT (TTM)
-$234.75M
Net Income (TTM)
-$199.61M
Balance Sheet
Total Assets (Q)
$692.41M
Total Debt (Q)
$3.03M
Total Liabilities (Q)
$37.00M
Book Value Per Share (Q)
$9.87
Cash Flow
Cash from Operations (TTM)
-$186.19M
Cash from Investing (TTM)
$164.61M
Cash from Financing (TTM)
$1.89M
Net Change in Cash (TTM)
-$19.70M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.23
7-Day Total Return
-10.70%
30-Day Total Return
-5.67%
60-Day Total Return
13.50%
90-Day Total Return
10.77%
Year to Date Total Return
-9.07%
1-Year Total Return
-8.68%
2-Year Total Return
-0.51%
3-Year Total Return
-33.66%
5-Year Total Return
45.38%
52-week Low
Apr 09, 2025 - $14.40
52-week High
Jan 08, 2025 - $29.05
Valuation
Market Cap
$1.78B - Small Cap
Enterprise Value
$1.15B
Price/Sales (TTM)
306.54
Price/Book (Q)
2.71
Dividends and Shares
Shares Outstanding
66.39
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.celldex.com
Phone Number
908 200 7500
Address
Perryville III Building
Suite 220 - 53 Frontage Road
Hampton, NJ 08827
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The... more
NASDAQ 11/05/2025 10:16AM Eastern Quotes delayed